Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Tavag Mrinalini
Cost-Effectiveness of Bevacizumab and Ranibizumab for Newly Diagnosed Neovascular Macular Degeneration
Ophthalmology
Ophthalmology
Related publications
Safety and Efficacy of Ranibizumab and Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration
European Ophthalmic Review
Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration
New England Journal of Medicine
Medicine
Baseline Predictors for One-Year Visual Outcomes With Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration
Ophthalmology
Ophthalmology
Ranibizumab Monotherapy in Neovascular Age-Related Macular Degeneration With Pigment Epithelial Detachment
Journal of Clinical & Experimental Ophthalmology
Ranibizumab in Neovascular Age-Related Macular Degeneration: A 5-Year Follow-Up
Clinical Ophthalmology
Ophthalmology
Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration
Archives of Ophthalmology
PSS10 Cost- Effectiveness of Ranibizumab in Patients With Neovascular Wet Age-Related Macular Degeneration (Namd) at the Mexican Social Security System (Imss)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration
JAMA Ophthalmology
Ophthalmology
Effect of ARMS2 Gene Polymorphism on Intravitreal Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration
Genetics and Molecular Research
Medicine
Genetics
Molecular Biology
